• What is stroke?

"Fast treatment is vital but difficult"

15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.

What is stroke?

Stroke occurs as a consequence of hemorrhagic insult or artery occlusion due to underlying cardiovascular disease. Pivotal in beneficial treatment of stroke is instant intervention.

Stroke remains a leading cause of death and disability throughout the world, and both associated human suffering and financial costs are overwhelming. Given that age is one of the most defined risk factors for stroke the increasing ageing of the European population implies a growing number of persons at risk.

Stroke - the sudden killer

The brain needs a constant blood supply, which provides vital nutrients and oxygen to the neurons in the brain to function. Stroke is usually sudden; it can be due to ischemia (lack of blood flow) caused by blockage (thrombosis, arterial embolism), or a hemorrhage. Typical effects are loss of motor functions and/or vision. About a third of people who have a stroke make a significant recovery within a month. But most stroke survivors will have long-term problems. It may take a year or longer for them to make the best possible recovery. In the most severe cases, strokes can be fatal or cause long-term disability.

The drugs used which are the only once with proven effects against neurological damage in acute stroke are blood clot dissolutions using recombinant tissue plasminogen activator.
Unfortunately this is only effective for patients who present within 3 hours after onset of ischemic stroke.
If hemorrhage has occurred in the brain anticoagulants should not be administered as this might worsen the condition.

" I waked and sat up...when I felt a confusion and indistinctness in my head which lasted, I suppose about half a minute. Soon after I perceived that I had suffered a paralytic stroke, and that my
Speech was taken from me" - Dr Samuel Johnson, 1783

A new treatmentmodel for stroke

There is an unmet need for an efficacious therapy that can be administered instantly, as well as beyond three hours, to achieve neuroprotection in addition to thrombolysis.  COUNTERSTROKE will develop an efficient drug candidate, an Affibody molecule, targeting the inflammatory mediator HMGB1 which can be used during a substantially prolonged time frame. Curious about the science behind counterstoke?

Want to know more aboute stroke? Visit the National Stroke Association